Review of radiopharmaceutical therapy in prostate cancer
Radiopharmaceuticals therapy (RPT) has been a major breakthrough in the treatment of prostate cancer. This therapy utilizes radioactive isotopes targeted specifically to prostate cancer, combining the advantages of systemic therapy with targeted radiation. The 2 currently FDA approved agents are <sup>223</sup>Ra and <sup>177</sup>Lu-PSMA-617 which have both demonstrated an overall survival advantage. In this review we will discuss the approved agents, their similarities and differences, treatment sequencing, combinations with other therapies, as well as future directions of this promising field.
Authors
- Sean R. Miller (ORCID: https://orcid.org/0000-0001-5059-2209)
- Benjamin L. Viglianti (ORCID: https://orcid.org/0000-0002-8471-4988)
- Yuni K. Dewaraja (ORCID: https://orcid.org/0000-0002-3920-6925)
- Zachery R. Reichert
Institutions
- University of Michigan (US)
- Michigan Medicine (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Urologic Oncology Seminars and Original Investigations
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.urolonc.2026.111030
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00